3 Dividend Stocks to Buy and Hold for 10 Years

The article identifies Pfizer, Abbott Laboratories, and Medtronic as long-term healthcare income-stock candidates, citing their product pipelines, growth opportunities, and durable dividend records. Pfizer offers a 6.2% forward dividend yield despite weak post-COVID results and pending patent cliffs, while Abbott reported Q2 comparable sales growth of 4.8% to $12.6 billion and adjusted EPS growth of 4% to $1.31. Medtronic posted fiscal Q1 2027 revenue growth of 13.7% to $9.8 billion, supported by an 88% increase in cardiac-ablation sales, and expects separating its lower-margin diabetes business to create a more focused company.

Analysis

The investable distinction is quality of earnings rather than dividend yield. ABT has the cleanest setup: device-led growth can absorb weaker nutrition results, while a scaled oncology-diagnostics platform would create cross-selling opportunities across hospital labs and screening channels. The offset is that any large EXAS transaction shifts the story from organic execution to integration, leverage, and antitrust risk; the market should not capitalize revenue synergies until procurement savings and test-volume retention are visible.

MDT's diabetes separation is principally a multiple and margin-mix catalyst, not an automatic earnings catalyst. A focused core MDT should command a better peer comparison against procedure-device franchises such as BSX and SYK if cardiac ablation and robotic surgery translate from launch momentum into recurring consumables and installed-base utilization. The separated diabetes entity could also become a strategic asset for insulin-pump peers, but dis-synergies, stranded costs, and the final capital-allocation framework are the near-term variables that matter.

PFE remains the weakest risk-adjusted expression despite headline yield support. Pipeline optionality will not offset the valuation drag unless management demonstrates that new-product growth exceeds losses from aging brands and that free cash flow covers both the dividend and debt reduction without further large acquisitions. Consensus is likely underweighting the chance that obesity is an expensive, late-entry category where efficacy, tolerability, and manufacturing capacity—not merely a promising candidate—determine economics.

Over the next 1-3 months, MDT separation disclosures and ABT's deal financing/integration detail are more actionable than broad healthcare sentiment. Over 6-18 months, procedure growth durability and margin conversion determine whether either rerates; a deceleration in ablation growth, lower Libre growth, or a reduction in PFE's post-launch revenue outlook would falsify the respective bullish cases.

Key Decisions for Investors

• Initiate a 6-12 month long MDT / short PFE pair, sized beta-neutral. MDT has identifiable restructuring and procedure-utilization catalysts, while PFE requires multiple clinical and commercial assumptions to support rerating; exit if MDT core-device organic growth decelerates materially for two consecutive quarters or separation costs exceed management's framework.
• Keep ABT on a watch-list rather than chase immediately: add only after EXAS financing, regulatory remedies, and retention assumptions are disclosed. The attractive setup is long ABT if management can preserve device-margin progression while funding the transaction without a meaningful leverage-driven buyback pause; avoid if diagnostic-volume attrition or deal remedies impair expected returns.
• For MDT holders, use a defined-risk 6-9 month call spread around the expected separation milestone rather than outright incremental equity if event timing remains uncertain. The thesis requires disclosure of standalone margins, dis-synergies, and capital structure; absent those data, an outright pre-event overweight is not justified.
• Avoid treating PFE's dividend as a standalone long catalyst. Reassess only following evidence of sustained non-COVID product growth, improved net-debt trajectory, and pipeline data that establish a differentiated obesity profile; dividend coverage deterioration or another acquisition would be a clear downside trigger.